{"schema_version":"secwatch.filing_event.v1","accession":"0001420800-25-000038","form_type":"8-K","ticker":"ENOV","cik":"0001420800","company_name":"Enovis CORP","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.371292+00:00","generated_at":"2026-05-16T23:35:06.536099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Enovis Q3 sales up 9% to $549M; raises FY adjusted EBITDA and EPS guidance","bullets":["Q3 net sales $549M (+9% reported, +7% organic); Recon +12% reported, P&R +6% reported.","Net loss $571M including $548M non-cash goodwill impairment; adjusted EPS $0.75.","Divested Dr. Comfort (Diabetic Footcare) unit in Oct for up to $60M.","Raised FY2025 guidance: revenue $2.24-2.27B, adj. EBITDA $395-405M, adj. EPS $3.10-3.25."],"urls":{"canonical":"https://secwatch.observer/filing/0001420800-25-000038","json":"https://secwatch.observer/filing/0001420800-25-000038.json","markdown":"https://secwatch.observer/filing/0001420800-25-000038.md","text":"https://secwatch.observer/filing/0001420800-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420800/000142080025000038/0001420800-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420800/000142080025000038/cfx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:35:06.536099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}